AVITA Medical (RCEL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$75.6M

Revenue (quarter)

$21.7M

Revenue growth (year over year)

+17.83%

Gross profit (trailing twelve months)

$61.7M

Gross margin

81.56%

Net income (trailing twelve months)

−$43.1M

Net income (quarter)

−$7.7M

Net income growth (year over year)

+22.75%

Net margin

−56.96%

Return on equity

—

EPS (trailing twelve months)

−$1.44

Book value per share

−$0.90

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

158.27%

Payout ratio

—

Dividend yield

—

Company profile

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

• Is AVITA Medical (RCEL) profitable?

  No. AVITA Medical reported a net loss of $43.1M over the trailing twelve months.

• How much revenue does AVITA Medical (RCEL) make?

  AVITA Medical generated $75.6M in revenue over the trailing twelve months, up 17.83% year over year.

• How do I buy stock in AVITA Medical (RCEL)?

  RCEL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.